Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.

Ni S, Wang H, Zhu X, Wan C, Xu J, Lu C, Xiao L, He J, Jiang C, Wang W, He Z.

Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.

2.

HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models.

Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, Fusco A, Heim MH, Ng CK, Pallante P, Terracciano LM, Piscuoglio S.

Neoplasia. 2016 Dec;18(12):724-731. doi: 10.1016/j.neo.2016.10.002. Epub 2016 Nov 14.

3.

MiR-4500 is epigenetically downregulated in colorectal cancer and functions as a novel tumor suppressor by regulating HMGA2.

Yu FY, Tu Y, Deng Y, Guo C, Ning J, Zhu Y, Lv X, Ye H.

Cancer Biol Ther. 2016 Nov;17(11):1149-1157. Epub 2016 Sep 29.

4.

Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.

Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, Lee SC, Kim JH.

Exp Mol Med. 2016 Aug 26;48:e255. doi: 10.1038/emm.2016.73.

5.

In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.

Hopper RK, Moonen JR, Diebold I, Cao A, Rhodes CJ, Tojais NF, Hennigs JK, Gu M, Wang L, Rabinovitch M.

Circulation. 2016 May 3;133(18):1783-94. doi: 10.1161/CIRCULATIONAHA.115.020617. Epub 2016 Apr 4.

6.

The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.

Hillion J, Roy S, Heydarian M, Cope L, Xian L, Koo M, Luo LZ, Kellyn K, Ronnett BM, Huso T, Armstrong D, Reddy K, Huso DL, Resar LMS.

Gynecol Oncol. 2016 Jun;141(3):580-587. doi: 10.1016/j.ygyno.2016.03.020. Epub 2016 Apr 8.

7.

The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Sumter TF, Xian L, Huso T, Koo M, Chang YT, Almasri TN, Chia L, Inglis C, Reid D, Resar LM.

Curr Mol Med. 2016;16(4):353-93. Review.

8.

HMGA1-pseudogenes and cancer.

De Martino M, Forzati F, Arra C, Fusco A, Esposito F.

Oncotarget. 2016 May 10;7(19):28724-35. doi: 10.18632/oncotarget.7427. Review.

9.

High Mobility Group A2 protects cancer cells against telomere dysfunction.

Natarajan S, Begum F, Gim J, Wark L, Henderson D, Davie JR, Hombach-Klonisch S, Klonisch T.

Oncotarget. 2016 Mar 15;7(11):12761-82. doi: 10.18632/oncotarget.6938.

10.

Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas.

D'Angelo D, Esposito F, Fusco A.

Front Med (Lausanne). 2015 Jun 8;2:39. doi: 10.3389/fmed.2015.00039. eCollection 2015. Review.

11.

Deregulation of HMGA1 expression induces chromosome instability through regulation of spindle assembly checkpoint genes.

Pierantoni GM, Conte A, Rinaldo C, Tornincasa M, Gerlini R, Federico A, Valente D, Medico E, Fusco A.

Oncotarget. 2015 Jul 10;6(19):17342-53.

12.

HMGA proteins as modulators of chromatin structure during transcriptional activation.

Ozturk N, Singh I, Mehta A, Braun T, Barreto G.

Front Cell Dev Biol. 2014 Mar 6;2:5. doi: 10.3389/fcell.2014.00005. eCollection 2014. Review.

13.

HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs.

Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, Arra C, Pierantoni GM, Fusco A.

Oncotarget. 2014 Sep 30;5(18):8341-54.

14.

Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.

Willenbrock S, Wagner S, Reimann-Berg N, Moulay M, Hewicker-Trautwein M, Nolte I, Murua Escobar H.

PLoS One. 2014 Jun 10;9(6):e98788. doi: 10.1371/journal.pone.0098788. eCollection 2014.

15.

Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype.

Federico A, Forzati F, Esposito F, Arra C, Palma G, Barbieri A, Palmieri D, Fedele M, Pierantoni GM, De Martino I, Fusco A.

Biol Open. 2014 Apr 11;3(5):372-8. doi: 10.1242/bio.20146759.

16.

The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Huso TH, Resar LM.

Expert Opin Ther Targets. 2014 May;18(5):541-53. doi: 10.1517/14728222.2014.900045. Epub 2014 Mar 31. Review.

17.

Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Yanagisawa BL, Resar LM.

Expert Rev Anticancer Ther. 2014 Jan;14(1):23-30. doi: 10.1586/14737140.2013.859988.

18.

HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.

Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G.

Oncotarget. 2013 Aug;4(8):1293-308.

19.

Overexpression of high mobility group A1 protein in human uveal melanomas: implication for prognosis.

Qu Y, Wang Y, Ma J, Zhang Y, Meng N, Li H, Wang Y, Wei W.

PLoS One. 2013 Jul 23;8(7):e68724. doi: 10.1371/journal.pone.0068724. Print 2013.

20.

HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells.

Natarajan S, Hombach-Klonisch S, Dröge P, Klonisch T.

Neoplasia. 2013 Mar;15(3):263-80.

Supplemental Content

Support Center